Matt Mailman

Matt Mailman is currently the Global Early Detection Strategy Lead for Type 1 Diabetes at Sanofi, where they focus on optimizing outcomes for individuals at the pre-symptomatic stage of the disease. Previously, they held various leadership positions including Senior Director at Johnson & Johnson, where they developed solutions for early detection of lung cancer and led integrated strategies in neuroscience and digital health. Matt's extensive background encompasses roles at companies like Eli Lilly and the National Center for Biotechnology Information, with a strong emphasis on precision medicine, biomarkers, and informatics. They earned a postdoctoral degree in Bioinformatics from the University of Pennsylvania.